Clinical Trial Update: Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on sacituzumab govitecan with or without pembrolizumab for metastatic triple-negative breast cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Status: RECRUITING